

Matthew T Campbell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8098210/publications.pdf>

Version: 2024-02-01

52
papers

3,793
citations

516710

16
h-index

223800

46
g-index

53
all docs

53
docs citations

53
times ranked

5040
citing authors

#	ARTICLE	IF	CITATIONS
1	Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1103-1115.	27.0	1,824
2	Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. <i>Nature Medicine</i> , 2018, 24, 1804-1808.	30.7	521
3	Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. <i>Nature Medicine</i> , 2020, 26, 1733-1741.	30.7	282
4	Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. <i>Nature Medicine</i> , 2020, 26, 1845-1851.	30.7	193
5	Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. , 2019, 7, 253.		103
6	Phase 2 study of pembrolizumab in patients with advanced rare cancers. , 2020, 8, e000347.		95
7	Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 101-101.	1.6	75
8	Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis. <i>Oncologist</i> , 2020, 25, 252-258.	3.7	62
9	Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis. <i>European Journal of Cancer</i> , 2018, 104, 188-194.	2.8	58
10	Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial. <i>Investigational New Drugs</i> , 2021, 39, 1405-1410.	2.6	35
11	Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. <i>Nature Communications</i> , 2022, 13, 1970.	12.8	34
12	Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma. , 2020, 8, e001009.		30
13	Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction. <i>Frontiers in Oncology</i> , 2021, 11, 621591.	2.8	29
14	A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. <i>Science Translational Medicine</i> , 2022, 14, eabm6420.	12.4	29
15	Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e205-e208.	1.9	24
16	MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. <i>Nature Communications</i> , 2022, 13, 1797.	12.8	23
17	Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. <i>BJU International</i> , 2022, 129, 610-620.	2.5	22
18	Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 6375.	12.8	22

#	ARTICLE	IF	CITATIONS
19	Survival following cytoreductive nephrectomy: a comparison of existing prognostic models. <i>BJU International</i> , 2020, 126, 745-753.	2.5	20
20	Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies. <i>Oncologist</i> , 2021, 26, 476-482.	3.7	19
21	Optimizing management of upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 492-498.	1.6	18
22	Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. <i>Oncologist</i> , 2021, 26, 558-e1098.	3.7	18
23	Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a sin. <i>BJU International</i> , 2016, 118, 264-271.	2.5	17
24	Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study. <i>Urology</i> , 2016, 89, 83-89.	1.0	17
25	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. , 2021, 9, e002552.		16
26	Combination antiangiogenic tyrosine kinase inhibition and anti- PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. <i>Cancer Medicine</i> , 2021, 10, 2341-2349.	2.8	15
27	Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. , 2021, 9, e002850.		15
28	Targeting advanced urothelial carcinoma-developing strategies. <i>Current Opinion in Oncology</i> , 2019, 31, 207-215.	2.4	14
29	Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2021, 4, e2122998.	5.9	13
30	Epidemiological risk factors for adrenocortical carcinoma: A hospital-based case-control study. <i>International Journal of Cancer</i> , 2020, 146, 1836-1840.	5.1	12
31	Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. <i>European Urology</i> , 2023, 6, 228-232.	5.4	11
32	Phase I Trial of Sunitinib and Temezirolimus in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 218-224.	1.9	10
33	Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature. <i>European Urology Focus</i> , 2018, 4, 442-454.	3.1	10
34	The role of metastatic burden in cytoreductive/consolidative radical cystectomy. <i>World Journal of Urology</i> , 2019, 37, 2691-2698.	2.2	10
35	A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature. <i>Frontiers in Endocrinology</i> , 2020, 11, 594264.	3.5	10
36	Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1239-1246.	3.6	9

#	ARTICLE	IF	CITATIONS
37	Paraneoplastic pemphigus manifesting in a patient treated with pembrolizumab for urothelial carcinoma. <i>JAAD Case Reports</i> , 2021, 10, 82-84.	0.8	8
38	Very Late Recurrence in Germ Cell Tumor of the Testis: Lessons and Implications. <i>Cancers</i> , 2022, 14, 1127.	3.7	8
39	Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. <i>Molecular Cancer Research</i> , 2021, 19, 395-402.	3.4	7
40	Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. <i>Journal of Urology</i> , 2021, 206, 1258-1267.	0.4	7
41	New Directions in Treatment of Metastatic or Advanced Pheochromocytomas and Sympathetic Paragangliomas: an American, Contemporary, Pragmatic Approach. <i>Current Oncology Reports</i> , 2022, 24, 89-98.	4.0	7
42	Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. <i>International Journal of Cancer</i> , 2021, 149, 387-393.	5.1	6
43	The State of Immune Checkpoint Inhibition in Urothelial Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 96-100.	2.0	5
44	Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 176-182.	1.9	5
45	Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 790.e17-790.e23.	1.6	3
46	Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 837.e9-837.e17.	1.6	3
47	A phase II trial to evaluate pemetrexed clinical responses in relation to tumor methylthioadenosine phosphorylase (MTAP) gene status in patients with previously treated metastatic urothelial carcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 385-385.	1.6	3
48	Clinicopathological analysis and outcomes of inflammatory myofibroblastic tumours of the urinary bladder. <i>BJU International</i> , 2022, 130, 604-610.	2.5	3
49	Emerging treatments in advanced urothelial cancer. <i>Current Opinion in Oncology</i> , 2020, 32, 232-239.	2.4	2
50	Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e16-e24.	1.9	1
51	Predictive capacity of a miRNA panel in identifying teratoma in post-chemotherapy consolidation surgeries. <i>BJUI Compass</i> , 2023, 4, 81-87.	1.3	1
52	Reply by Authors. <i>Journal of Urology</i> , 2021, 206, 1267.	0.4	0